"I was on vacation, so I left my meter and test strips at home." Sound familiar? Here: strategies to tackle this and other common challenges.
Juice is good food and does not contribute to disruption of glucose-insulin homeostasis, as long as its 100% real fruit juice, according to a new study.
Increased risk for CV events and severe hypoglycemia in T2D patients treated with β-blockers seems reason enough to rethink this Rx.
One theory is that metformin taken during insulin treatment impacts energy intake and so supports weight loss. A quick look at a new study suggests something else.
We do all we can to help patients do all they can to manage their diabetes. We all need to be able to trust the supply chain, from start to finish.
Click through these 5 statements about the "gliflozin" class of diabetes drugs for a test of your recall and retention.
Take our 6-question True or False spot-check quiz on ADA vaccine recommendations.
Ask patients to reframe the readings as a call to action, a signal to tweak, to fine-tune.
The first-to-market hybrid closed loop CGM and "smart" insulin pens are 2 of our picks for 2017’s best tech advances in diabetes management.
How can we harness the electronic resources we already have at our disposal—and use them to help everyone better engage?
Is GLP-1 part of the answer to why cardiac mortality tends to be higher in diabetes patients treated with intensive glycemic control?
Five studies on the impact of diabetes drugs on CV outcomes get the editors' nod for the most promising results in 2017 diabetes research. Find out which 5!
Insulin pump/sensor combos, continuous glucose sensors . . . a wrap-up of these and other advances in endocrinology in 2017, plus some caveats for the future.
ShugaTrak, Glucose Buddy, OnTrack -- 3 of the 5 apps we highlight that are designed to make diabetes monitoring seamless for all.
More intensive reduction of A1c, lipids, and blood pressure did, however, result in a significantly reduced rate of cerebrovascular events.